Actionable news
0
All posts from Actionable news
Actionable news in AZN: ASTRAZENECA PLC,

AstraZeneca's Drug Deal - M&A Daily

Welcome to the Hyperkalemia edition of M&A Daily

Sifting the World members receive exclusive access to event driven, value investing, and arbitrage opportunities. You can receive actionable research first on StW. Meanwhile, here are some examples of such opportunities in today's market.

AstraZeneca

AstraZeneca (NYSE:AZN) agreed to acquire ZS (NASDAQ:ZSPH) in an all-cash deal valued at about $2.7 billion. ZSPH holders get $90 in cash per share. The $0.81 net spread offers an 8% annual return to a close by mid-December. This deal price is a 42% premium on the pre-deal market price. The deal strengthens the buyer's cardiovascular and metabolic disease portfolio. The deal target is selling before its hyperkalemia drug ZS-9 hits the market.

Global peak sales are expected to be over a billion dollars per year. The deal strengthens the buyer's cardiovascular and metabolic disease portfolio. The product will compete in the market with Relypsa's (NASDAQ:RLYP) hyperkalemia drug Veltassa.

Alibaba

Alibaba (NYSE:BABA) is buying Youku Tudou (NYSE:YOKU) in an all-cash transaction valued at $5.4 billion...


More